ENGINEERED PROTEINS TO REPAIR OR REGROW DAMAGED HEART MUSCLE CELLS AND TISSUE
Associate Professor Dan Hesselson,
Head of the Centre for Biomedical AI,
Centenary Institute
Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | July 2026
Associate Professor Dan Hesselson leads the Centre for Biomedical AI at the Centenary Institute.
He is an internationally trained research leader in regenerative medicine, focusing on cells and organs affected by heart disease, diabetes and cancer. His work uses insights from the study of basic regenerative processes to identify novel therapeutic targets for these devastating diseases.
His work with zebrafish, which started at University of California San Francisco (UCSF) and was expanded at the Garvan Institute, made significant contributions to our understanding of the molecular mechanisms of regeneration in this highly regenerative model system.
At the Centenary Institute, he is focused on exploiting these breakthroughs in basic science to develop new therapeutic strategies using the power of Directed Evolution to generate potent and highly specific biologic drugs.
His research is investigating new ways to repair the heart and improve outcomes for individuals recovering from heart attacks or living with heart disease, aiming to address a critical gap in cardiac care.
While current treatments can manage symptoms, they cannot restore heart function once muscle cells are lost. This irreversible damage is why heart failure remains a leading cause of death worldwide.
Associate Professor Hesselson’s research aims to address this challenge by developing therapies based on engineered proteins capable of repairing or regrowing damaged heart muscle cells and tissue.
Source: Supplied and adapted from Centenary Institute media release (June 2026)
-
Pathogenicity, modelling & treatment of inherited retinal Stargardt disease
Dr Di Huang is a Research Associate at the Lions Eye Institute (LEI), working with A/Professor Fred Chen and Dr Sam McLenachan. Her research focuses on developing a robust platform of retinal pigment epithelium cells and retinal organoids derived from patient-specific induced pluripotent stem cells to model inherited retinal diseases, particularly Stargardt disease (STGD1).
-
Liver cancer biomarkers, risk prediction & progression
Dr. Rodrigo Carlessi is an expert in Cancer Genomics and Molecular Biology, with an extensive track record in liver cancer research. He leads the Cancer Genomics Group within the Liver Disease and Regeneration Laboratory at the Curtin Medical Research Institute. He has an impressive publication record, with 43 manuscripts that have collectively garnered over 2,680 citations. His research leverages cutting-edge genomics and transcriptomics technologies, as well as long-read DNA sequencing, to explore mechanisms, identify biomarkers, and develop therapeutic targets in liver disease and cancer.
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
